New Data Showing that Transgene and NEC's Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023 - New Phase I data confirm promising immunogenicity and efficacy profile of TG4050, an ...
